Dr Karunakar Sukuru of Catalent explains how lipid-based softgels address physiological barriers to oral peptide delivery as approvals increase.
|Articles|December 16, 2013
- BioPharm International-12-16-2013
- Volume 2013 eBook
- Issue 1
Creating Better Medicines through Better Conjugation
Author(s)Cynthia A. Challener
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.
Advertisement
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.
from BioPharm International’s 2013 Innovation Updates and Strategies eBook.
Articles in this issue
almost 13 years ago
Recovering Patent Life with Patent Term Extensionalmost 13 years ago
Strategic Outsourcing in Clinical Developmentalmost 13 years ago
Leveraging Development Strengths Drives Therapies to Marketalmost 13 years ago
Driving Innovation in Biopharmaceuticalsalmost 13 years ago
Crowdfunding Biopharmaceutical Innovationalmost 13 years ago
Restructuring for Biopharmaceutical SuccessAdvertisement
Related to this article
Phase 1 HCXT-2001, an oral macrocyclic IL-23R peptide, could be paired with emvistegrast as a daily oral IBD treatment, according to Gilead.
METiS TechBio will apply its AI-driven AiLNP ionizable lipid platform to discover LNPs designed to deliver therapeutics beyond the liver, under a collaboration with Eli Lilly worth up to $1.1 billion in milestones.
Inhaled EXO-CD24 kept 85% of patients with ARDS free of respiratory failure at day 7 vs 33.3% with placebo in a 90-patient phase 2b trial.
This year's PharmSci 360 will close with a plenary on fixing drug development economics given by Averin's Dr Berry.
Full Phase 3 TroFuse-005 data presented at ESMO 2026 show the TROP2-directed ADC sacituzumab tirumotecan cut the risk of death by 32% vs chemotherapy, and an FDA decision is expected by June 2027.
A patient with relapsing MS died of septic pneumonia 44 days after zola-cel CAR T infusion, as all 60 dose level 2 patients stayed off DMTs.
BioNTech and DualityBio's HER2-directed ADC modestly improved progression-free survival over chemotherapy in DYNASTY-Breast02, but higher interstitial lung disease rates and an established competitor limit its potential in this setting.
Advertisement
Advertisement
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
3
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
4
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
5